Published 7 days ago • loading... • Updated 4 days ago

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Summary by cancernetwork.com

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

cancernetwork.com

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

4 days ago

Read Full Article

Clinical Trials Arena

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved its primary goal.The post Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint appeared first on Clinical Trials Arena.

6 days ago

Read Full Article

targetedonc.com

Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options.

7 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year